Literature DB >> 22971327

Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany.

A Hamprecht1, D Buchheidt, J J Vehreschild, O A Cornely, B Spiess, G Plum, T V Halbsguth, N Kutsch, D Stippel, P Kahl, T Persigehl, A Steinbach, B Bos, M Hallek, M J Vehreschild.   

Abstract

We report the first culture-proven case of invasive aspergillosis (IA) caused by azole-resistant Aspergillus fumigatus in a patient with acute myeloid leukaemia in Germany. IA presented as breakthrough infection under posaconazole prophylaxis. Analysis of the resistance mechanism revealed the TR/L98H mutation in the cyp51A gene, which indicates an environmental origin of the strain. This case underscores the need for monitoring azole resistance in Aspergillus spp. and for routine susceptibility testing of moulds.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22971327

Source DB:  PubMed          Journal:  Euro Surveill        ISSN： 1025-496X


  12 in total

1.  Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.

Authors:  Seyedmojtaba Seyedmousavi; Roger J M Brüggemann; Jacques F Meis; Willem J G Melchers; Paul E Verweij; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

2.  Environmental isolates of azole-resistant Aspergillus fumigatus in Germany.

Authors:  Oliver Bader; Jana Tünnermann; Anna Dudakova; Marut Tangwattanachuleeporn; Michael Weig; Uwe Groß
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

Review 3.  Azole Resistance in Aspergillus fumigatus in Patients with Cystic Fibrosis: A Matter of Concern?

Authors:  A Hamprecht; F Morio; O Bader; P Le Pape; J Steinmann; E Dannaoui
Journal:  Mycopathologia       Date:  2017-06-26       Impact factor: 2.574

4.  Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis.

Authors:  Seyedmojtaba Seyedmousavi; Johan W Mouton; Willem J G Melchers; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

5.  In Vivo Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis.

Authors:  Seyedmojtaba Seyedmousavi; Johan W Mouton; Willem J G Melchers; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

6.  Azole-resistant Aspergillus fumigatus isolate with the TR34/L98H mutation in both a fungicide-sprayed field and the lung of a hematopoietic stem cell transplant recipient with invasive aspergillosis.

Authors:  Steffi Rocchi; Etienne Daguindau; Frédéric Grenouillet; Eric Deconinck; Anne-Pauline Bellanger; Dea Garcia-Hermoso; Stéphane Bretagne; Gabriel Reboux; Laurence Millon
Journal:  J Clin Microbiol       Date:  2014-02-19       Impact factor: 5.948

7.  First detection of TR46/Y121F/T289A and TR34/L98H alterations in Aspergillus fumigatus isolates from azole-naive patients in Denmark despite negative findings in the environment.

Authors:  K M T Astvad; R H Jensen; T M Hassan; E G Mathiasen; G M Thomsen; U G Pedersen; M Christensen; O Hilberg; M C Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191

Review 8.  Molecular Tools for the Detection and Deduction of Azole Antifungal Drug Resistance Phenotypes in Aspergillus Species.

Authors:  Anna Dudakova; Birgit Spiess; Marut Tangwattanachuleeporn; Christoph Sasse; Dieter Buchheidt; Michael Weig; Uwe Groß; Oliver Bader
Journal:  Clin Microbiol Rev       Date:  2017-10       Impact factor: 26.132

9.  Prevalence and mechanism of triazole resistance in Aspergillus fumigatus in a referral chest hospital in Delhi, India and an update of the situation in Asia.

Authors:  Anuradha Chowdhary; Cheshta Sharma; Shallu Kathuria; Ferry Hagen; Jacques F Meis
Journal:  Front Microbiol       Date:  2015-05-08       Impact factor: 5.640

10.  Incidence of Cyp51 A key mutations in Aspergillus fumigatus-a study on primary clinical samples of immunocompromised patients in the period of 1995-2013.

Authors:  Birgit Spiess; Patricia Postina; Mark Reinwald; Oliver A Cornely; Axel Hamprecht; Martin Hoenigl; Cornelia Lass-Flörl; Peter-Michael Rath; Jörg Steinmann; Thomas Miethke; Melchior Lauten; Silke Will; Natalia Merker; Wolf-Karsten Hofmann; Dieter Buchheidt
Journal:  PLoS One       Date:  2014-07-29       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.